Home    Back

 Drug    DrugBank | All Description Patterns

   e.g. "Sirolimus", "Adalimumab"

A    B    C    D    E    F    G    H     I     J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    other

321 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   Drug (Description in trials) 
 [Number of descriptions] 		  KEGG DRUG *   KEGG GENES * 
 [Number of genes] 		  KEGG PATHWAY 
 [Number of pathways] 		  Disease ID * 
 [Number of diseases] 
 1   ABX-464  [4] Abx464; Abx464 100mg; Abx464 25mg; Abx464 50mg;   -   -   -   [3]
46,
96,
97
 2   AC-430  [1] Ac430;   -   -   -   [1]
46
 3   ADL5859  [1] Adl5859;   -   -   -   [1]
46
 4   AMG 108  [1] Amg 108;   -   -   -   [1]
46
 5   AZD-5672  [1] Azd5672;   -   -   -   [1]
46
 6   AZD-9056  [2] Azd9056; Azd9056 hydrochloride;   -   -   -   [2]
46,
96
 7   Abatacept  [27] Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept;   D03203   [2] CD80, CD86   [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   [24]
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 8   Acalabrutinib  [1] Acalabrutinib;   D10893   [1] BTK   [7] B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency   [1]
46
 9   Aceclofenac  [1] Aceclofenac;   D01545   [3] PTGES, PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [1]
46
 10   Acetaminophen  [8] Acetaminophen; Acetaminophen tab 650mg; Acetaminophen tablets; Acetaminophen/paracetamol; Oxycodone/acetaminophen; Paracetamol (acetaminophen); Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen;   D00217   [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [13]
3,
6,
13,
34,
35,
46,
49,
51,
70,
86,
231,
256,
271
 11   Acetate  [76] 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate;   -   -   -   [40]
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299
 12   Acetylsalicylic acid  [2] Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,;   D00109   [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [10]
13,
22,
34,
46,
49,
51,
86,
113,
158,
231
 13   Activated charcoal  -  D03251   -   -   [8]
6,
13,
46,
85,
86,
96,
97,
298
 14   Acyclovir  [1] Acyclovir;   D00222   -   -   [5]
13,
28,
46,
53,
60
 15   Adalimumab  [50] Adalimumab; Adalimumab (40 mg); Adalimumab (ada); Adalimumab (d2e7); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg eow or ew; Adalimumab 40 mg sc every other week; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab and infliximab; Adalimumab injection; Adalimumab injection [humira]; Adalimumab pfs and pen; Adalimumab prn; Adalimumab with methotrexate; Adalimumab, etanercept, golimumab or infliximab; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Double-blind adalimumab; Etanercept or adalimumab; Fitc-adalimumab; Gp2017 (adalimumab biosimilar); Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Ol adalimumab 40 mg; Open-label adalimumab; Sb5 (proposed biosimilar to adalimumab); Start adalimumab in monotherapy; Tnf blockers (infliximab, adalimumab, etanercept); Treatment with adalimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D02597   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [15]
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 16   Adefovir  [1] Adefovir;   D02768   -   -   [1]
46
 17   Ademetionine  -  D07128   -   -   [15]
6,
14,
22,
43,
44,
46,
47,
49,
50,
60,
84,
93,
96,
97,
172
 18   Adenine  -  D00034   -   -   [1]
46
 19   Adenosine  [4] 2-cda, 2-chloro-2’-deoxy-beta-d-adenosine; 2-cda, 2-chloro-2’-deoxy-ß-d-adenosine; Adenosine; Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv);   D00045   [4] ADORA1, ADORA2A, ADORA2B, ADORA3   [12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   [5]
13,
46,
53,
58,
65
 20   Alemtuzumab  [18] Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alemtuzumab (campath ); Alemtuzumab (campath); Alemtuzumab (gz402673); Alemtuzumab 0.2 mg; Alemtuzumab 0.3 mg; Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab and rituximab; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alemtuzumab, rituximab; Filgrastim, alemtuzumab; Transplant conditioning with mobilization and alemtuzumab; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D02802   -   -   [17]
13,
15,
19,
20,
46,
49,
51,
60,
63,
65,
85,
96,
164,
234,
284,
285,
326
 21   Alendronic acid  [1] Alendronic acid;   D00939
 D07119 		  [1] FDPS   [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis   [7]
19,
41,
46,
50,
271,
274,
299
 22   Alfacalcidol  [3] Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alfacalcidol; Ibandronate+alfacalcidol+calcium;   D01518   [1] VDR   [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   [6]
41,
46,
49,
50,
96,
235
 23   Alkaline Phosphatase  [6] Alkaline phosphatase; Bovine intesastinal alkaline phosphatase (biap); Bovine intestinal alkaline phosphatase (biap); Bovine-calf alkaline phosphatase (biap); Bovine-calf alkaline phosphatase biap; Human recombinant tissue non-specific alkaline phosphatase fusion protein;   -   -   -   [3]
46,
97,
172
 24   Allopurinol  [4] Allopurinol; Allopurinol sandoz 100 mg, tabletten; Allopurinol sodium; Azathioprine and allopurinol;   D00224   [1] XDH   [5] Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism   [6]
6,
46,
57,
66,
96,
97
 25   Alpha-Linolenic Acid  -  -   -   -   [1]
46
 26   Aluminium  [3] Aluminium; Aluminium phosphate; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate;   -   -   -   [1]
46
 27   Aluminium phosphate  [2] Aluminium phosphate; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate;   -   -   -   [1]
46
 28   Aminopterin  [2] Aminopterin; Ld-aminopterin;   D02527   -   -   [1]
46
 29   Amoxapine  [2] Amoxapine; Amoxapine & dipyridamole;   D00228   [2] SLC6A2, SLC6A4   [2] Serotonergic synapse, Synaptic vesicle cycle   [1]
46
 30   Amoxicillin  [7] Amoxicillin; Amoxicillin and tetracycline; Amoxicillin hydrate; Amoxicillin, metronidazole and tetracycline; Clartihromycin, amoxicillin, and omeprazole; Lansoprazole, amoxicillin, clarithromycin; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication);   D00229
 D02925
 D07452 		  -   -   [6]
6,
46,
63,
96,
97,
222
 31   Anakinra  [8] Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate;   D02934   [2] IL1R1, IL1R2   [15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer   [17]
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 32   Angiotensin II  [2] Angiotensin ii; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin);   D00150
 D02014 		  [2] AGTR1, AGTR2   [14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   [7]
17,
19,
46,
66,
86,
222,
224
 33   Anifrolumab  [4] Anifrolumab; Anifrolumab (medi-546); Anifrolumab 1000 mg; Anifrolumab 300 mg;   D11082   [2] IFNAR1, IFNAR2   [17] Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway   [2]
46,
49
 34   Apremilast  [7] Apremilast; Apremilast (cc-10004); Apremilast 20 mg; Apremilast 30 mg; Apremilast 30mg; Apremilast tablet 20 mg; Apremilast tablet 30 mg bid;   D08860   [4] PDE4A, PDE4B, PDE4C, PDE4D   [5] Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway   [5]
46,
50,
56,
97,
271
 35   Atacicept  [5] Atacicept; Atacicept 150 mg; Atacicept 25 mg; Atacicept 75 mg; Atacicept 75 milligram (mg);   D09704   [2] TNFSF13, TNFSF13B   [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis   [4]
13,
46,
49,
66
 36   Atorvastatin  [9] Atorvastatin; Atorvastatin 10mg; Atorvastatin 20mg; Atorvastatin calcium; Atorvastatin tablet 20 mg; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Lisinopril, losartan, and atorvastatin; Untreated to atorvastatin treatment;   D00258
 D00887
 D07474 		  [1] HMGCR   [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   [17]
13,
46,
49,
51,
58,
63,
79,
84,
88,
93,
96,
160,
222,
225,
265,
271,
299
 37   Azathioprine  [33] 5-asa, prednisone, azathioprine or remicade; Azathioprine; Azathioprine (aza); Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine 25 mg; Azathioprine and allopurinol; Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine or mycophenolate mofetil; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azathioprine/prednisone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Continuation of azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Early immunosuppressants (azathioprine, methotrexate); Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Overencapsulated azathioprine (imuran) 50 mg tablet; Prednisone - azathioprine; Products containing azathioprine or 6-mercaptopurine; Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine;   D00238
 D03033 		  -   -   [18]
11,
13,
19,
35,
42,
43,
44,
45,
46,
49,
65,
66,
85,
94,
95,
96,
97,
162
 38   BMS-582949  [2] Bms-582949; Bms-582949 and methotrexate;   -   -   -   [1]
46
 39   BMS-817399  [1] Bms-817399;   -   -   -   [1]
46
 40   BMS-986104  [1] Bms-986104;   -   -   -   [1]
46
 41   BMS-986142  [5] Bms-986142; Bms-986142 200mg; Bms-986142 350mg; Methotrexate, leucovorin and bms-986142; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142;   -   -   -   [2]
46,
53
 42   Baminercept  [3] Baminercept; Baminercept alfa; Baminercept alfa (bg9924);   D08866   [1] LTB   [3] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis   [4]
13,
46,
53,
97
 43   Baricitinib  [3] Baricitinib; Baricitinib, olumiant®; Tofacitinib/baricitinib;   D10308   [2] JAK1, JAK2   [32] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   [8]
41,
46,
49,
50,
93,
107,
265,
325
 44   Belatacept  [1] Belatacept;   D03222   [2] CD80, CD86   [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   [1]
46
 45   Belimumab  [21] Belimumab; Belimumab 1 mg/kg; Belimumab 10 mg; Belimumab 10 mg/kg; Belimumab 10 mg/kg plus standard therapy; Belimumab 100 mg sc; Belimumab 10mg/kg; Belimumab 200 mg sc; Belimumab 200 mg/ml; Belimumab 4 mg/kg; Belimumab for iv; Belimumab for sc; Belimumab injection; Belimumab or benlysta; Belimumab plus early vaccination; Belimumab plus late vaccination; Benlysta (belimumab); Benlysta® (belimumab); Benlysta™ (belimumab); Gsk1550188 (belimumab); Sc belimumab 200 mg;   D03068   [1] TNFSF13B   [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis   [8]
11,
43,
44,
46,
49,
51,
53,
222
 46   Benzimidazole  [2] Benzimidazole; Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 h-benzimidazole;   -   -   -   [1]
46
 47   Benzyl alcohol  -  D00077   -   -   [3]
28,
46,
271
 48   Betamethasone  [6] Betamethasone; Betamethasone acibutate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Intra-articular compound betamethasone; Intraarticular betamethasone; Phosphate and betamethasone acetate, 2 ml.;   D00244
 D00972
 D01357
 D01402
 D01637
 D02032
 D02286 		  [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [6]
2,
46,
65,
90,
96,
235
 49   Bifenthrin  -  -   -   -   [2]
6,
46
 50   Bimekizumab  [1] Bimekizumab;   D11550   [2] IL17A, IL17F   [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation   [3]
46,
97,
271
 51   Binetrakin  -  D03117   -   -   [1]
46
 52   Bortezomib  [6] Bortezomib; Bortezomib (velcade®); Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Combination of a single dose anti-cd20 antibody and bortezomib; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab;   D03150   [1] PSMB5   [1] Proteasome   [13]
11,
26,
28,
46,
49,
51,
61,
63,
66,
228,
256,
288,
331
 53   Branebrutinib  -  D11478   [1] BTK   [7] B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency   [1]
46
 54   Bucillamine  [2] Bucillamine; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin);   D01809   -   -   [1]
46
 55   Bupivacaine  [8] Bupivacaine; Bupivacaine & triamcinolone acetonide; Bupivacaine hydrochloride; Bupivacaine injection 0.5%; Bupivacaine/epinephrine/dexamethasone; Lap tap bupivacaine/epinephrine; Liposomal bupivacaine; Us tap bupivacaine/epinephrine;   D01450
 D07552 		  [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   [7]
46,
53,
70,
96,
168,
226,
298
 56   Buprenorphine  [2] Buprenorphine; Buprenorphine transdermal patch;   D00836
 D07132 		  [2] OPRK1, OPRM1   [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   [2]
46,
70
 57   CCX-354  [4] Ccx 354; Ccx 354-c; Ccx354; Ccx354-c;   -   -   -   [1]
46
 58   CRx-139  [1] Crx-139;   -   -   -   [1]
46
 59   Caffeine  [5] Caffeine; Caffeine 100 mg; Caffeine 100-200 mg bid; Caffeine alkaloid; Dextromethorphan and caffeine;   D00528
 D01453 		  [11] ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A   [22] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   [6]
2,
6,
46,
78,
96,
97
 60   Calcitriol  [4] Calcitriol; Calcitriol & calcium; Delayed release 6mp or calcitriol vs. purinethol; Rapamycin-calcitriol combination;   D00129   [1] VDR   [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   [8]
37,
46,
49,
66,
96,
158,
235,
326
 61   Calcium  [25] Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium;   -   -   -   [24]
6,
13,
19,
46,
49,
51,
65,
68,
75,
79,
84,
93,
94,
95,
96,
97,
214,
215,
222,
224,
235,
265,
298,
299
 62   Calcium Carbonate  [3] Amorphous calcium carbonate; Calcium carbonate; Calcium carbonate and alphacalcidol;   D00932
 D10802 		  -   -   [7]
13,
19,
46,
75,
96,
235,
299
 63   Calcium Citrate  [2] Calcium citrate; Calcium citrate with vitamin d2;   D00933   -   -   [3]
46,
84,
235
 64   Canakinumab  [7] Canakinumab; Canakinumab (acz885); Canakinumab (company code: acz885d); Canakinumab (investigational); Canakinumab (proposed); Canakinumab (who approval pending); Canakinumab injection [ilaris];   D09315   [1] IL1B   [40] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection   [9]
46,
56,
84,
106,
107,
108,
113,
266,
269
 65   Cannabidiol  [6] Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg;   D10915   [2] CNR1, CNR2   [4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis   [14]
2,
6,
13,
46,
95,
96,
97,
140,
144,
145,
157,
158,
193,
271
 66   Carbaspirin calcium  -  D03385   -   -   [1]
46
 67   Carbonate ion  -  -   -   -   [10]
2,
13,
17,
19,
46,
75,
96,
127,
235,
299
 68   Celecoxib  [7] Celecoxib; Celecoxib (celebrex); Celecoxib 200 milligrams; Celecoxib 200mg capsule; Celecoxib 400 milligrams; Celecoxib, celebrex®; Fixed dose combination ciprofloxacin/celecoxib;   D00567   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [9]
2,
3,
34,
46,
70,
89,
96,
161,
271
 69   Certolizumab pegol  [11] 99mtc-s-hynic certolizumab pegol; Certolizumab pegol; Certolizumab pegol (cdp870); Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol (rinn); Certolizumab pegol + methotrexate (mtx); Certolizumab pegol 400 mg; Cimzia certolizumab pegol 200 mg/ml solution for injection; Infliximab, adalimumab, certolizumab pegol;   D03441   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [6]
37,
46,
96,
97,
226,
271
 70   Cetrorelix  [1] Cetrorelix;   D01685
 D07665 		  [1] GNRHR   [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction   [1]
46
 71   Chicken  [2] Chicken; Chicken type ii collagen;   -   -   -   [1]
46
 72   Chloride ion  -  -   -   -   [17]
6,
11,
13,
14,
34,
46,
51,
96,
97,
127,
168,
193,
227,
228,
288,
297,
299
 73   Chlorine  -  -   -   -   [2]
46,
271
 74   Chloroquine  [4] Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Hydroxychloroquine or chloroquine;   D02125
 D02366
 D03469 		  -   -   [4]
46,
49,
95,
130
 75   Chloroxylenol  -  D03473   -   -   [4]
6,
13,
46,
168
 76   Cholecalciferol  [9] 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3;   D00188   [1] VDR   [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   [15]
6,
13,
19,
20,
34,
46,
49,
53,
60,
65,
96,
97,
228,
298,
299
 77   Chromic chloride  -  D03479   -   -   [1]
46
 78   Chromium  [1] Chromium;   -   -   -   [1]
46
 79   Ciclosporin  [4] Aerolised liposomal ciclosporin a; Ciclosporin; Ciclosporin (ciclosporinium); Ciclosporin a;   D00184   [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   [30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   [44]
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 80   Citalopram  [2] 20mg daily citalopram; Citalopram;   D00822
 D07704 		  [1] SLC6A4   [2] Serotonergic synapse, Synaptic vesicle cycle   [3]
8,
46,
127
 81   Citric acid  [3] Citric acid; Citric acid based mouthwash; Sodium picosulfate, magnesium oxide and citric acid;   D00037
 D01222 		  -   -   [4]
46,
53,
245,
291
 82   Clazakizumab  [1] Clazakizumab;   D10312   -   -   [2]
46,
96
 83   Clindamycin  [1] Clindamycin;   D00277
 D01073
 D01990
 D02132 		  -   -   [1]
46
 84   Clofarabine  [2] Campath, busulfan, clofarabine; Clofarabine;   D03546   [3] POLA1, POLA2, RRM1   [6] DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   [9]
19,
20,
40,
46,
49,
60,
96,
234,
326
 85   Cobalt  [1] Cobalt;   -   -   -   [1]
46
 86   Cobiprostone  [1] Cobiprostone;   D08893   -   -   [1]
46
 87   Cod liver oil  [1] Cod liver oil;   D03578   -   -   [1]
46
 88   Corn  [3] Corn; Corn oil capsules; Corn/soy oil;   -   -   -   [2]
46,
240
 89   Corticotropin  [8] Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension;   D00146   [1] MC2R   [5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway   [12]
2,
13,
46,
49,
50,
66,
75,
78,
84,
145,
193,
222
 90   Creatine  [4] Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide;   -   -   -   [12]
1,
2,
5,
6,
8,
13,
46,
49,
50,
113,
156,
201
 91   Creatinine  [1] Creatinine;   D03600   -   -   [3]
2,
46,
60
 92   Curcumin  [5] Bio-enhanced curcumin soft gelatin capsule; Curcumin; Curcumin (longvida™); Curcumin supplement; Ifn beta 1 a + curcumin (bcm 95);   -   -   -   [10]
13,
46,
49,
67,
74,
94,
96,
97,
139,
299
 93   Cyclophosphamide  [48] Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Campath, fludarabine, cyclophosphamide; Cyclophosphamide; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide (drug); Cyclophosphamide + pred; Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide 50mg; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and atg; Cyclophosphamide and steroids; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide monohydrate; Cyclophosphamide post transplant; Cyclophosphamide(ctx); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Cyclophosphamide-prednisone-azathioprine; Cyclophosphamide/glatiramer acetate; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; High-dose cyclophosphamide; Iv cyclophosphamide; Lenalidomide, dexamethasone and cyclophosphamide; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; Prednisone, cyclophosphamide; Rituximab and cyclophosphamide iv; Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 		  -   -   [43]
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 94   Denosumab  [4] Denosumab; Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab);   D03684   [1] TNFSF11   [7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis   [7]
46,
50,
93,
95,
96,
274,
299
 95   Dexamethasone  [35] Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone;   D00292
 D00975
 D01510
 D01615
 D01632
 D01948
 D02174
 D02591
 D02592 		  [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [20]
13,
16,
28,
35,
46,
53,
63,
65,
70,
74,
75,
81,
83,
84,
90,
96,
97,
222,
296,
299
 96   Dextromethorphan  [9] Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan;   D00848
 D03742
 D03744 		  [5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D   [17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway   [9]
2,
6,
8,
13,
46,
78,
96,
97,
156
 97   Diacerein  [4] Ccp-020 (diacerein 1% ointment); Diacerein; Diacerein 1% ointment; Diacerein 1% ointment topical formulation;   D07270   -   -   [2]
36,
46
 98   Diazepam  [2] Diazepam; Diazepam, melatonin;   D00293   [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   [7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   [3]
46,
155,
298
 99   Diclofenac  [9] Comparator: diclofenac; Comparator: diclofenac sodium; Diclofenac; Diclofenac + omeprazole; Diclofenac 50 milligrams; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac sodium; Diclofenac sodium topical gel; Diclofenac sr;   D00903
 D00904
 D07816 		  [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [4]
13,
34,
46,
271
 100   Digoxin  [3] Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Digoxin; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142;   D00298   [4] ATP1A1, ATP1A2, ATP1A3, ATP1A4   [18] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway   [2]
8,
46
 101   Dimethyl fumarate  [4] Dimethyl fumarate; Dimethyl fumarate (dmf); Dimethyl fumarate [dmf]; Tecifdera (dimethyl fumarate);   D03846   [1] KEAP1   [4] Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis   [5]
13,
46,
49,
51,
86
 102   Dipyridamole  [7] Amoxapine & dipyridamole; Dipyridamole; Dipyridamole tab 25 mg; Extended release dipyridamole 200mg/aspirin 25mg; Prednisolone & dipyridamole; Prednisolone-dipyridamole; Z102 (prednisolone and dipyridamole).;   D00302   [2] PDE4A, PDE5A   [6] Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway   [5]
46,
49,
51,
66,
224
 103   Donepezil  [4] Donepezil; Donepezil hci (drug); Donepezil hydrochloride; Donepezil sandoz;   D00670
 D07869 		  [1] ACHE   [2] Cholinergic synapse, Glycerophospholipid metabolism   [9]
5,
6,
13,
46,
78,
124,
127,
156,
206
 104   Doxycycline  [7] Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline);   D00307
 D02129
 D03903
 D03904
 D07876 		  -   -   [15]
13,
23,
28,
46,
84,
85,
89,
96,
97,
158,
162,
167,
227,
280,
299
 105   Dronabinol  [4] Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Dronabinol; Dronabinol capsule 2,5 mg; Dronabinol capsule 2.5. mg;   D00306   [2] CNR1, CNR2   [4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis   [5]
2,
13,
46,
271,
298
 106   Edoxaban  [1] Edoxaban;   D09546
 D09710 		  [1] F10   [1] Complement and coagulation cascades   [2]
46,
88
 107   Efalizumab  [1] Efalizumab;   D03959   [1] ITGAL   [11] Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis   [9]
11,
13,
37,
46,
49,
53,
61,
95,
96
 108   Eldecalcitol  [1] Eldecalcitol;   D07578   [1] VDR   [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   [1]
46
 109   Enalapril  [4] Enalapril; Enalapril and other angiotensin converting enzyme inhibitors; Enalapril maleate; Enalapril valsartan methylprednisone;   D00621
 D07892 		  [1] ACE   [4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system   [4]
19,
46,
66,
113
 110   Enoxaparin  [1] Enoxaparin;   D03674
 D07510 		  [1] SERPINC1   [1] Complement and coagulation cascades   [1]
46
 111   Entecavir  [1] Entecavir;   D04008
 D07896 		  -   -   [5]
46,
56,
96,
97,
271
 112   Epinephrine  [4] Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine;   D00095
 D00996
 D02149 		  [9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3   [13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   [9]
6,
13,
46,
86,
96,
168,
226,
231,
256
 113   Ergocalciferol  [2] Ergocalciferol; Ergocalciferol (vitamin d2);   D00187   [1] VDR   [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   [5]
46,
84,
96,
97,
299
 114   Erythropoietin  [4] Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo);   D03231   [1] EPOR   [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   [9]
2,
6,
13,
22,
46,
47,
70,
95,
96
 115   Esomeprazole  [3] Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium);   D01984
 D04056
 D07917
 D09339 		  [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [6]
6,
46,
86,
98,
298,
299
 116   Estradiol  [8] 5% lidocaine/5 mg/ml estradiol compound cream; Estradiol; Estradiol 2 mg; Estradiol hemihydrate; Ethinyl estradiol; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg;   D00105
 D01413
 D01617
 D01953
 D04061
 D04063
 D04064
 D04065 		  [2] ESR1, ESR2   [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   [5]
13,
46,
49,
226,
299
 117   Eszopiclone  [1] Eszopiclone;   D02624   [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   [7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   [3]
6,
13,
46
 118   Etanercept  [39] 50 mg etanercept; Adalimumab, etanercept, golimumab or infliximab; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Enbrel (etanercept); Etanercept; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (enbrel); Etanercept (enbreltm); Etanercept (full-dose); Etanercept (half-dose); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50 mg solution for injection; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, methotrexate, prednisolone; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tapering or discontinuation of etanercept; Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D00742   [2] LTA, TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [15]
15,
28,
35,
38,
39,
46,
50,
53,
56,
60,
85,
228,
271,
285,
298
 119   Ethanol  [7] Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel;   D00068
 D02798
 D04855
 D06542 		  -   -   [49]
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 120   Ethinylestradiol  [1] Ethinylestradiol;   D00554   [1] ESR1   [8] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   [4]
13,
46,
49,
299
 121   Etodolac  [2] Etodolac; Other non steroidal anti-inflammatory drugs (nsaids) except etodolac;   D00315   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [1]
46
 122   Etoricoxib  [6] Etoricoxib; Mk0663, etoricoxib; Part i - etoricoxib 60 mg; Part i - etoricoxib 90 mg; Part ii- etoricoxib 60 mg; Part ii- etoricoxib 90 mg;   D03710   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [2]
46,
271
 123   Evobrutinib  [2] Evobrutinib; M2951 (other name: evobrutinib);   -   -   -   [3]
13,
46,
49
 124   Famotidine  [2] Famotidine; Famotidine 20 mg;   D00318   [1] HRH2   [3] Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   [3]
6,
46,
86
 125   Fentanyl  [5] Dexmedetomidine and fentanyl; Fentanyl; Fentanyl citrate; Fentanyl transdermal patch; Transdermal fentanyl matrix, gabapentin;   D00320
 D01399 		  [1] OPRM1   [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   [5]
46,
70,
85,
215,
231
 126   Filgotinib  [4] Filgotinib; Inn - filgotinib; Proposed inn - filgotinib; Propsoed inn - filgotinib;   D10871   [1] JAK1   [26] EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   [6]
46,
53,
96,
97,
222,
271
 127   Filgrastim  [6] Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim);   D03235   [1] CSF3R   [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   [28]
2,
6,
13,
16,
25,
26,
28,
34,
35,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
85,
96,
113,
164,
283,
284,
285,
331
 128   Fish oil  [10] Combination fish oil and borage seed oil; Combination of fish oil and colesevelam; Fish oil; Fish oil concentrate; Fish oil supplement; Fish oil, gamma-linolenic acid; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Lipoic acid (la) with fish oil and la without fish oil; Omega-3 fatty acid fish oil supplement;   -   -   -   [7]
13,
46,
49,
66,
96,
260,
299
 129   Fletikumab  -  -   -   -   [1]
46
 130   Florasulam  -  -   -   -   [1]
46
 131   Fludarabine  [23] Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine and atg; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Busulfan, fludarabine, atg, tli; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Fludarabine; Fludarabine (flu); Fludarabine monophosphate; Fludarabine phosphate; Fludarabine phosphate 30 mg; Fludarabine phosphate 40 mg; Fludarabine, busulfan, thymoglobulin; Fludarabine, cyclophosphamide; Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Fludarabine/busulfan; Sq fludarabine; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D01907
 D07966 		  [1] RRM1   [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   [17]
13,
28,
36,
46,
49,
51,
60,
61,
62,
65,
85,
96,
164,
283,
284,
285,
326
 132   Fludeoxyglucose F-18  [1] Fludeoxyglucose f 18;   -   -   -   [8]
6,
13,
34,
46,
53,
84,
127,
300
 133   Fluorine F-18  [1] Fluorine f 18;   D05860   -   -   [4]
40,
46,
49,
96
 134   Flurbiprofen  [3] Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Flurbiprofen; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142;   D00330
 D01475
 D02290 		  [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [2]
13,
46
 135   Flutriciclamide F-18  -  -   -   -   [1]
46
 136   Folic acid  [5] Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid;   D00070   -   -   [11]
6,
13,
46,
49,
62,
84,
86,
96,
97,
254,
284
 137   Fontolizumab  [1] Fontolizumab;   D04242   [1] IFNG   [33] African trypanosomiasis, Allograft rejection, Amoebiasis, Antigen processing and presentation, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hepatitis C, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Leishmaniasis, Malaria, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Proteasome, Rheumatoid arthritis, Salmonella infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus   [1]
46
 138   Fostamatinib  [9] Fostamatinib; Fostamatinib 100 mg; Fostamatinib 150 mg; Fostamatinib 150 mg bid; Fostamatinib 50 mg blue film-coated tablet; Fostamatinib disodium; Fostamatinib disodium (r935788); Fostamatinib disodium tablet 100 mg; Fostamatinib disodium tablet 150 mg;   D09347   [1] SYK   [15] B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis   [4]
46,
49,
61,
66
 139   GLPG-0259  [1] Glpg0259;   -   -   -   [1]
46
 140   GS-5745  [3] Gs-5745; Gs-5745 iv; Gs-5745 sc;   -   -   -   [2]
46,
97
 141   GSK-3117391  [1] Gsk3117391;   -   -   -   [1]
46
 142   GW-274150  [2] Gw274150; Gw274150 tablets;   -   -   -   [1]
46
 143   GW-406381  [1] Gw406381;   -   -   -   [1]
46
 144   Gadobutrol  [1] Gadobutrol;   D07420   -   -   [3]
13,
22,
46
 145   Gadolinium  [6] Gadolinium; Gadolinium contrast; Gadolinium for abdomen; Gadolinium for lower back; Gadolinium-based contrast; Standard gadolinium contrast;   -   -   -   [6]
13,
34,
46,
58,
65,
305
 146   Gamolenic acid  -  D07213   -   -   [1]
46
 147   Ginger  [1] Ginger;   D06744   -   -   [1]
46
 148   Ginseng  [4] American ginseng; American ginseng extract ht-1001; Ginseng; Korean red ginseng;   D06772   -   -   [3]
13,
46,
53
 149   Ginsenosides  -  -   -   -   [1]
46
 150   Glucosamine  [1] Glucosamine;   D04334   -   -   [2]
46,
271
 151   Gold  [3] Gold; Gold nanocrystals; Sodium aurothiomalate (intramuscular gold);   -   -   -   [5]
2,
6,
13,
46,
171
 152   Golimumab  [36] Adalimumab, etanercept, golimumab or infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Exposure to golimumab; Golimumab; Golimumab (cnto 148); Golimumab (glm); Golimumab (optimization); Golimumab 1 mg per kg; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg per kg; Golimumab 2 mg/kg iv; Golimumab 200 mg; Golimumab 4 mg per kg; Golimumab 400 mg; Golimumab 50 mg; Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg; Golimumab 50 mg injections; Golimumab dose 1; Golimumab dose 2; Golimumab final vialed product (fvp); Golimumab injection; Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Golimumab prefilled syringe; Golimumab treatment optimization.; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Iv golimumab; Sc golimumab; Simponi (golimumab); Simponi® (golimumab); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D04358   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [5]
46,
84,
96,
97,
271
 153   Grapefruit  [2] Grapefruit; Grapefruit juice;   -   -   -   [5]
6,
46,
50,
83,
97
 154   Green tea leaf  [1] Green tea leaf;   D06903   -   -   [5]
6,
17,
28,
46,
96
 155   HE3286  [1] He3286;   -   -   -   [2]
46,
97
 156   HZT-501  [1] Hzt-501;   -   -   -   [1]
46
 157   Hepatitis A Vaccine  [3] Epaxal berna (virosomal hepatitis a vaccine); Hepatitis a vaccine; Hepatitis a vaccine and tetanus vaccine;   -   -   -   [3]
46,
96,
97
 158   Human interleukin-2  [2] Human interleukin-2; Recombinant human interleukin-2 (rhil-2);   -   -   -   [14]
2,
13,
35,
46,
49,
51,
55,
56,
63,
65,
95,
96,
97,
271
 159   Hyaluronic acid  [5] Hyaluronic acid; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid inhalation solution; Hyaluronic acid/chondroitin sulfate; Standard care hyaluronic acid eye drops;   D08043   -   -   [7]
46,
53,
70,
97,
226,
231,
299
 160   Hydroxide ion  -  -   -   -   [4]
46,
96,
97,
284
 161   Hydroxychloroquine  [16] Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine;   D08050   -   -   [18]
13,
41,
46,
48,
49,
53,
56,
66,
84,
89,
90,
96,
222,
234,
254,
271,
298,
299
 162   Ibandronate  [2] Ibandronate; Ibandronate+alfacalcidol+calcium;   D08056   [1] FDPS   [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis   [2]
46,
49
 163   Ibuprofen  [5] Ibuprofen; Ibuprofen 200mg; Ibuprofen pch tablet 600mg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen;   D00126
 D01122
 D04490
 D06606 		  [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [6]
13,
46,
65,
113,
271,
299
 164   Iguratimod  [2] Iguratimod; Iguratimod (careram);   D01146   [1] NFKB1   [67] AGE-RAGE signaling pathway in diabetic complications, Acute myeloid leukemia, Adipocytokine signaling pathway, Amoebiasis, Antifolate resistance, Apoptosis, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Chronic myeloid leukemia, Cocaine addiction, Cytosolic DNA-sensing pathway, Epithelial cell signaling in Helicobacter pylori infection, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Longevity regulating pathway, MAPK signaling pathway, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prolactin signaling pathway, Prostate cancer, RIG-I-like receptor signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway   [3]
46,
53,
271
 165   Imatinib  [6] Bevacizumab (avastin) and imatinib mesylate (gleevec); Imatinib; Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (gleevec); Imatinib mesylate 400mg capsule;   D01441
 D08066 		  [3] ABL1, KIT, PDGFRA   [32] Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   [11]
13,
28,
34,
35,
46,
51,
85,
86,
87,
89,
162
 166   Infliximab  [66] 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D02598   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [23]
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 167   Interleukin-10  [2] Guna-interleukin 10; Interleukin 10;   -   -   -   [1]
46
 168   Iodine  [1] Iodine;   D00108   -   -   [3]
28,
46,
88
 169   Isopropyl alcohol  -  D00137   -   -   [10]
13,
46,
58,
84,
96,
97,
269,
271,
279,
298
 170   Itacitinib  [1] Itacitinib;   D10944   [1] JAK1   [26] EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   [4]
46,
60,
97,
228
 171   JNJ-40346527  [5] Jnj-40346527; Jnj-40346527-aac; Jnj-40346527-aac - capsule - 50 mg; Prv-6527 (jnj-40346527); Prv-6527(jnj-40346527);   -   -   -   [2]
46,
96
 172   KC706  [1] Kc706;   -   -   -   [2]
35,
46
 173   Ketoprofen  [1] Ketoprofen;   D00132   [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [1]
46
 174   Lacosamide  [1] Lacosamide;   D07299   [2] SCN3A, SCN9A   [1] Taste transduction   [3]
2,
46,
149
 175   Lamivudine  [7] Abacavir sulfate, lamivudine and zidovudine; Combivir (zidovudine [azt] / lamivudine [3tc]); Lamivudine; Lamivudine/zidovudine; Lopinavir/ritonavir + zidovudine + lamivudine; Reverse transcriptase inhibitors: zidovudine, lamivudine, abacavir; Zidovudine/lamivudine;   D00353   -   -   [7]
2,
26,
42,
46,
135,
265,
325
 176   Leflunomide  [10] Leflunomide; Leflunomide (permitted, not necessary); Leflunomide 10mg tab; Leflunomide 20 mg tablets (geneva pharmaceutical); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Leflunomide 20mg tab; Leflunomide mylan; Leflunomide(lef); Leflunomide-sulfasalazine-hydroxychloroquine; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin);   D00749   [1] DHODH   [2] Metabolic pathways, Pyrimidine metabolism   [10]
11,
40,
46,
49,
53,
66,
162,
224,
271,
300
 177   Leucovorin  [2] Leucovorin; Methotrexate, leucovorin and bms-986142;   D01211
 D07986
 D07987 		  -   -   [2]
19,
46
 178   Levobupivacaine  [1] Levobupivacaine;   D01287
 D08116 		  [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   [1]
46
 179   Lidocaine  [8] 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine; Lidocaine injection 2%; Lidocaine patch 5%; Lidocaine releasing intravesical system - liris®; Local anesthesia (lidocaine hydrochloride);   D00358
 D02086
 D08127 		  [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   [10]
6,
13,
46,
84,
86,
97,
168,
226,
231,
256
 180   Lisinopril  [3] Coenzyme q10 and lisinopril; Lisinopril; Lisinopril, losartan, and atorvastatin;   D00362
 D08131 		  [1] ACE   [4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system   [5]
46,
66,
67,
113,
222
 181   Loratadine  [1] Loratadine;   D00364   [1] HRH1   [3] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   [3]
6,
13,
46
 182   Losartan  [8] Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan;   D00357
 D08146 		  [1] AGTR1   [14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   [18]
13,
17,
19,
46,
58,
66,
67,
85,
96,
97,
98,
113,
164,
167,
179,
215,
222,
299
 183   Lovastatin  [5] Lovastatin; Lovastatin 60 mg; Lovastatin ™; Lovastatin, then minocycline/lovastatin; Minocycline, then minocycline/lovastatin;   D00359   [1] HMGCR   [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   [10]
6,
34,
46,
79,
156,
160,
195,
206,
263,
310
 184   Loxoprofen  [3] Loxoprofen; Loxoprofen sodium hydrogel patch; Loxoprofen sodium tablet;   D08149   [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [2]
46,
271
 185   Lumiracoxib  [1] Lumiracoxib;   D03714   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [1]
46
 186   MK-0812  [2] Mk0812; Mk0812 / duration of treatment: 12 weeks;   -   -   -   [2]
13,
46
 187   MK-0873  [1] Mk-0873;   -   -   -   [1]
46
 188   MM-093  [1] Mm-093;   -   -   -   [1]
46
 189   Magnesium  [16] (s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; (s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; Magnesium; Magnesium citrate; Magnesium gluconate; Magnesium hydroxide; Magnesium oxide; Magnesium sulfate; Mineral boost (magnesium); Nexium (esomeprazole magnesium); Omeprazole magnesium; Saroglitazar magnesium 2 mg; Saroglitazar magnesium 4 mg; Sodium picosulfate, magnesium oxide and citric acid; Sodium picosulfate/magnesium citrate laxative; Sulfate, magnesium;   -   -   -   [15]
6,
11,
13,
46,
64,
93,
97,
166,
225,
235,
284,
291,
296,
297,
298
 190   Maraviroc  [2] All subjects will receive maraviroc 300mg orally twice a day for 6 weeks; Maraviroc;   D06670   [1] CCR5   [9] Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor   [2]
46,
84
 191   Masitinib  [10] Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate;   D10229   [1] KIT   [11] Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway   [6]
2,
5,
6,
13,
46,
96
 192   Mavrilimumab  [4] Mavrilimumab; Mavrilimumab 100 mg; Mavrilimumab 150 mg; Mavrilimumab 30 mg;   D09930   [1] CSF2RA   [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer   [2]
41,
46
 193   Melatonin  [10] 3 mg melatonin; 5 mg melatonin; Circadin ( inn= melatonin); Diazepam, melatonin; Dtr melatonin (nih cc pds); Hourly dosing of the nychtemeral secretion of melatonin; Melatonin; Melatonin cr; Melatonin pr; Melatonin(circadin®);   D08170   [2] MTNR1A, MTNR1B   [2] Circadian entrainment, Neuroactive ligand-receptor interaction   [8]
6,
13,
46,
49,
90,
97,
144,
202
 194   Meloxicam  [9] Aspirin and meloxicam; Meloxicam; Meloxicam 0.125 mg/kg; Meloxicam 0.25 mg/kg; Meloxicam ampoule; Meloxicam cf tablet 7,5mg; Meloxicam oral suspension; Meloxicam suppository; Meloxicam tablet;   D00969   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [4]
46,
49,
271,
296
 195   Mesalazine  [27] 1500mg mesalazine pellets; 250mg mesalazine pellets; 500mg mesalazine pellets; 750mg mesalazine pellets; Azathioprine or mesalazine; Mesalazine; Mesalazine (3,600 mg); Mesalazine (mesalamine); Mesalazine - tid 1000 mg; Mesalazine - tid 2x 500 mg; Mesalazine 1000 mg gastro-resistant tablets; Mesalazine 250mg; Mesalazine 250mg tablet and nitazoxanide 500mg oral tablet; Mesalazine 4g enema; Mesalazine 500 mg gastro-resistant tablets (salofalk® 500 mg); Mesalazine ec 500 mg; Mesalazine enema; Mesalazine sustained-release tablets; Mesalazine tablet; Mesalazine tablets; Mesalazine with hydrocortisone sodium succinate; Mesalazine, tripterygium glycosides; Mmx mesalamine/mesalazine; Mmx mesalamine/mesalazine (high dose); Mmx mesalamine/mesalazine (low dose); Overencapsulated mesalazine tablets; Spd476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine;   D00377   -   -   [4]
46,
96,
97,
164
 196   Metformin  [12] 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin;   D00944
 D04966 		  [2] PRKAA1, PRKAA2   [19] AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway   [17]
6,
13,
46,
49,
67,
75,
77,
81,
86,
113,
158,
206,
225,
233,
265,
285,
299
 197   Methamidophos  -  -   -   -   [12]
2,
11,
13,
19,
46,
49,
58,
70,
85,
98,
298,
300
 198   Methotrexate  [81] Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Cp-690,550 + methotrexate; Cyclosporin, methotrexate (gvhd prophylaxis); Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate lachema 5inj. sol; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate treatment; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level;   D00142
 D02115 		  [2] DHFR, DHFR2   [4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate   [33]
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 199   Methoxsalen  [2] Methoxsalen; Methoxsalen +ecp;   D00139   -   -   [3]
36,
46,
96
 200   Methylprednisolone  [29] Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 		  [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [36]
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 201   Methylprednisone  [2] Enalapril valsartan methylprednisone; Methylprednisone;   -   -   -   [3]
46,
66,
222
 202   Metronidazole  [6] 10% metronidazole ointment; Amoxicillin, metronidazole and tetracycline; Azithromycin + metronidazole; Metronidazole; Metronidazole capsule 50 mg; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication);   D00409
 D05016
 D05017 		  -   -   [8]
46,
51,
63,
94,
95,
96,
97,
291
 203   Midazolam  [6] Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam;   D00550
 D00696
 D05028 		  [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   [7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   [10]
2,
3,
6,
13,
46,
70,
96,
97,
231,
298
 204   Milnacipran  [1] Milnacipran;   D08222   [2] SLC6A2, SLC6A4   [2] Serotonergic synapse, Synaptic vesicle cycle   [2]
46,
49
 205   Minocycline  [7] Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin;   D00850
 D05045 		  -   -   [14]
2,
6,
8,
13,
46,
84,
85,
90,
94,
162,
201,
206,
280,
299
 206   Minodronic acid  [1] Minodronic acid;   -   -   -   [4]
6,
46,
93,
95
 207   Misoprostol  [1] Misoprostol;   D00419   [3] PTGER2, PTGER3, PTGER4   [9] Calcium signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways in cancer, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway   [2]
46,
271
 208   Mizoribine  [1] Mizoribine;   D01392   [2] IMPDH1, IMPDH2   [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   [8]
46,
49,
51,
53,
66,
94,
222,
224
 209   Montelukast  [8] 5 mg montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast; Montelukast sodium; Montelukast teva; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Montelukast/ singulair; Singulair (montelukast sodium);   D00529
 D08229 		  [1] CYSLTR1   [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction   [5]
13,
46,
85,
98,
228
 210   Morphine  [6] Intraarticular morphine; Morphine; Morphine hexal; Morphine pca; Morphine sulfate; Morphine sulphate in intrasite gel;   D00842
 D02271
 D08233 		  [1] OPRM1   [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   [4]
36,
46,
70,
86
 211   Moxifloxacin  [5] Avelox- moxifloxacin; Moxifloxacin; Moxifloxacin 400 mg; Moxifloxacin hydrochloride; Moxifloxacin infusion;   D00874
 D08237 		  -   -   [8]
2,
6,
46,
49,
85,
86,
240,
299
 212   Namilumab  [2] Namilumab; Namilumab (mt203);   -   -   -   [1]
46
 213   Naproxen  [12] Comparator: naproxen tablet 500 mg; Naproxen; Naproxen (ec-narosyn) delayed release tables, 375 (syntex (usa), inc.); Naproxen 10 mg/kg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Naproxen delayed release tables, 375 (gevena pharmaceuticals, inc.); Naproxen oral suspension; Naproxen pch tablet 500mg; Naproxen sodium 550mg tablet; Part i- naproxen 1000 mg; Part ii- naproxen 1000 mg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole);   D00118   [2] PTGS1, PTGS2   [21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [3]
13,
46,
271
 214   Natalizumab  [12] Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg0002 (natalizumab); Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Tysabri ® (natalizumab); Tysabri® (natalizumab);   D06886   [1] ITGA4   [14] Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection   [6]
13,
15,
25,
46,
63,
96
 215   Niclosamide  [1] Niclosamide;   D00436   -   -   [2]
46,
97
 216   Nicotinamide  [2] Nicotinamide; Nicotinamide riboside;   D00036   -   -   [8]
5,
6,
13,
46,
49,
53,
67,
162
 217   Nimesulide  [1] Nimesulide;   D01049   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [1]
46
 218   Nitric Oxide  [11] Inhaled nitric oxide; Inhaled nitric oxide & inopulse delivery; Inhaled nitric oxide - 30 mcg/kg ibw/hr; Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr; Inhaled nitric oxide 75 mcg/kg ibw/hr; Nitric oxide; Nitric oxide 160 ppm; Nitric oxide for inhalation; Nitric oxide generated by the geno nitrosyl delivery system; Nitric oxide plus oxygen; Nitric oxide supplement;   D00074   -   -   [7]
46,
85,
86,
98,
251,
294,
299
 219   Nitroglycerin  -  D00515   -   -   [1]
46
 220   Nivolumab  [1] Nivolumab;   D10316   [1] PDCD1   [3] Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway   [10]
13,
26,
41,
46,
49,
50,
51,
53,
96,
97
 221   Norethisterone  -  D00182
 D00953 		  [1] PGR   [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation   [4]
13,
46,
49,
299
 222   OTL-38  [1] Otl38;   -   -   -   [1]
46
 223   Ocrelizumab  [10] Ocrelizumab; Ocrelizumab / rhumab 2h7; Ocrelizumab 300 mg; Ocrelizumab 300mg; Ocrelizumab 300mg /10ml; Ocrelizumab 300mg/10ml; Ocrelizumab 500mg; Ocrelizumab 600 mg; Ocrelizumab dose 1; Ocrelizumab dose 2 and dose 3;   D05218   [1] MS4A1   [1] Hematopoietic cell lineage   [3]
13,
46,
49
 224   Ofatumumab  [8] Ofatumumab; Ofatumumab 100; Ofatumumab 300; Ofatumumab 30mg; Ofatumumab 3mg; Ofatumumab 60mg; Ofatumumab 700; Ofatumumab subcutaneous injection;   D09314   [1] MS4A1   [1] Hematopoietic cell lineage   [3]
13,
35,
46
 225   Olokizumab  [10] Olokizumab; Olokizumab 120 mg; Olokizumab 240 mg; Olokizumab 60 mg; Olokizumab 64 mg sc q2w; Olokizumab 64 mg sc q4w; Olokizumab 64mg q2w; Olokizumab 64mg q4w; Olokizumab q2w; Olokizumab q4w;   -   -   -   [2]
46,
96
 226   Omega-3 fatty acids  [6] Dietary supplement omega3 fatty acids aand vitamins; Lipoic acid and omega-3 fatty acids; Omega 3 fatty acids; Omega-3 fatty acids; Omega3 fatty acids; Triomar™ (omega-3 fatty acids);   -   -   -   [7]
13,
46,
49,
66,
79,
96,
299
 227   Omeprazole  [16] Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Naproxen 500 mg tablets (pn 200 minus omeprazole); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax;   D00455
 D01207
 D05259
 D05261 		  [2] ATP4A, ATP4B   [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   [15]
6,
8,
13,
46,
51,
85,
96,
97,
98,
225,
271,
282,
294,
298,
299
 228   Otelixizumab  [1] Otelixizumab;   D08959   [3] CD3D, CD3E, CD3G   [11] Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   [1]
46
 229   Oxycodone  [14] Extended-release oxycodone; Oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxycodone depot ”sandoz”, depot tablets; Oxycodone hydrochloride; Oxycodone naloxone prolonged release tablets; Oxycodone orion; Oxycodone/acetaminophen; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Pr oxycodone;   D03783
 D05312
 D05462 		  [3] OPRD1, OPRK1, OPRM1   [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway   [7]
6,
13,
46,
70,
226,
231,
298
 230   Oxygen  [9] Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture;   D00003   -   -   [18]
5,
6,
17,
46,
49,
70,
84,
85,
86,
88,
90,
96,
97,
193,
211,
226,
299,
330
 231   Ozoralizumab  [1] Ozoralizumab;   D09944   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [1]
46
 232   PF-06650833  [1] Pf-06650833;   -   -   -   [1]
46
 233   PF-06651600  [1] Pf-06651600;   -   -   -   [3]
46,
96,
97
 234   PH-797804  [1] Ph-797804;   -   -   -   [1]
46
 235   Paclitaxel  [2] Micellar paclitaxel for injection; Paclitaxel;   D00491
 D05333 		  [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   [3] Gap junction, Pathogenic Escherichia coli infection, Phagosome   [2]
46,
85
 236   Panax quinquefolius whole  -  -   -   -   [2]
13,
46
 237   Parecoxib  [1] Parecoxib;   D02709
 D03716 		  [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [2]
46,
271
 238   Paroxetine  [3] Paroxetine; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp;   D02260
 D02362
 D05374
 D05375 		  [1] SLC6A4   [2] Serotonergic synapse, Synaptic vesicle cycle   [3]
6,
13,
46
 239   Pateclizumab  -  D10187   [1] LTA   [7] Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor   [1]
46
 240   Peficitinib  [1] Peficitinib;   D10653   [3] JAK1, JAK2, JAK3   [34] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   [1]
46
 241   Pegsunercept  [2] Pegsunercept; Pegsunercept (peg stnf-ri);   D05393   [1] TNF   [61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [1]
46
 242   Pelubiprofen  [2] Pelubiprofen; Pelubiprofen 30 mg;   D01865   -   -   [1]
46
 243   Pertussis vaccine  [2] Pertussis vaccine; Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed);   D06514   -   -   [1]
46
 244   Phosphate ion  -  -   -   -   [29]
2,
3,
11,
12,
13,
28,
36,
46,
49,
51,
53,
60,
62,
65,
70,
78,
81,
83,
90,
96,
97,
164,
235,
256,
283,
284,
285,
286,
299
 245   Phylloquinone  [2] Phylloquinone; Phylloquinone (vitamin k1);   D00148   -   -   [4]
13,
46,
96,
288
 246   Pioglitazone  [6] Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl;   D00945
 D08378 		  [1] PPARG   [9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   [17]
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299
 247   Pirfenidone  [5] Pirfenidone; Pirfenidone 267 mg [esbriet]; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Sub-study: pirfenidone;   D01583   [6] CCL2, IL10, IL1A, IL1B, IL6, TNF   [80] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   [10]
34,
46,
50,
51,
58,
84,
85,
164,
222,
228
 248   Potassium  [4] Losartan potassium; Potassium; Potassium sparing diuretic; Potassium supplement;   D08403   -   -   [9]
46,
66,
67,
98,
115,
167,
179,
215,
235
 249   Potassium Iodide  -  D01016   -   -   [2]
46,
88
 250   Povidone-iodine  -  D00863   -   -   [2]
46,
88
 251   Pravastatin  [4] Lonafarnib, zoledronic acid, and pravastatin; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Pravastatin; Pravastatin sodium;   D00893
 D08410 		  [1] HMGCR   [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   [9]
13,
46,
49,
67,
79,
96,
164,
265,
333
 252   Prednisolone  [46] Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 		  [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [38]
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 253   Prednisone  [57] 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone);   D00473   [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [44]
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 254   Pregabalin  [3] Antioxidant plus pregabalin; Pregabalin; Pregabalin 75mg;   D02716   [4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4   [7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway   [5]
13,
36,
46,
70,
298
 255   Propofol  [3] Intubated with propofol (ip); Propofol; Propofol-lipuro;   D00549   [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   [7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   [8]
6,
21,
22,
34,
46,
84,
98,
296
 256   Puerarin  [3] Puerarin; Puerarin injection 400 mg; Puerarin tablet 50 mg;   -   -   -   [1]
46
 257   Pyrazole  -  -   -   -   [2]
46,
75
 258   Raloxifene  [2] Raloxifene; Raloxifene hydrochloride;   D02217
 D08465 		  [2] ESR1, ESR2   [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   [1]
46
 259   Ramelteon  [1] Ramelteon;   D02689   [2] MTNR1A, MTNR1B   [2] Circadian entrainment, Neuroactive ligand-receptor interaction   [3]
6,
8,
46
 260   Ramipril  [1] Ramipril;   D00421   [1] ACE   [4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system   [7]
46,
49,
66,
67,
113,
218,
257
 261   Rebamipide  [1] Rebamipide;   D01121   -   -   [4]
46,
53,
97,
271
 262   Regramostim  -  D05712   [1] CSF2RA   [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer   [4]
11,
46,
51,
229
 263   Revamilast  [1] Revamilast;   -   -   -   [1]
46
 264   Riboflavin  [4] Cofactor supplementation (thiamine, riboflavin, l-carnitine); Riboflavin; Riboflavin sodium phosphate injection; Riboflavin supplementation;   D00050
 D01622
 D01913 		  -   -   [9]
13,
38,
46,
49,
96,
97,
162,
168,
265
 265   Rifampicin  [1] Rifampicin;   D00211   -   -   [7]
6,
13,
17,
46,
84,
86,
299
 266   Rimacalib  [1] Rimacalib;   -   -   -   [1]
46
 267   Risedronic acid  [1] Risedronic acid;   D00942
 D03234
 D08484 		  [1] FDPS   [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis   [7]
46,
66,
93,
95,
96,
113,
274
 268   Rituximab  [52] Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab; Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab;   D02994   [1] MS4A1   [1] Hematopoietic cell lineage   [42]
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 269   Rivaroxaban  [1] Rivaroxaban;   D07086   [1] F10   [1] Complement and coagulation cascades   [2]
46,
49
 270   Ropivacaine  [1] Ropivacaine;   D04048
 D08490 		  [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   [3]
36,
46,
70
 271   Rosiglitazone  [6] Recombinant human growth hormone + rosiglitazone; Rosiglitazone; Rosiglitazone (avandia); Rosiglitazone extended release tablets; Rosiglitazone maleate; Rosiglitazone xr;   D00596
 D08491 		  [1] PPARG   [9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   [5]
46,
75,
97,
222,
265
 272   Rosuvastatin  [6] Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Rosuvastatin; Rosuvastatin 10 mg; Rosuvastatin 20mg; Rosuvastatin calcium;   D01915
 D08492 		  [1] HMGCR   [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   [8]
6,
46,
49,
51,
79,
96,
271,
299
 273   Roxithromycin  [1] Roxithromycin;   D01710   -   -   [2]
46,
299
 274   Rupatadine  [1] Rupatadine;   D07407   [2] HRH1, PTAFR   [4] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection   [1]
46
 275   SC12267  [2] Sc12267; Sc12267 (4sc-101);   -   -   -   [3]
46,
96,
97
 276   Sarilumab  [4] Sarilumab; Sarilumab 200 mg/1.14 ml subcutaneous solution [kevzara]_#1; Sarilumab sar153191; Sarilumab sar153191 (regn88);   D10161   [1] IL6R   [11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   [5]
41,
46,
84,
107,
271
 277   Secukinumab  [12] 150 mg double-blinded secukinumab; 150 mg open-label secukinumab; 300 mg double-blinded secukinumab; Ain457/secukinumab; Secukinumab; Secukinumab (150 mg); Secukinumab (75 mg); Secukinumab (ain457); Secukinumab 150 milligram [cosentyx]; Secukinumab 150mg; Secukinumab 300 mg, s.c.; Secukinumab 300mg;   D09967   [1] IL17A   [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation   [7]
13,
37,
41,
46,
160,
269,
271
 278   Sildenafil  [25] 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Acute (1 hour) sildenafil; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sildenafil therapy; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Sub-chronic (4 weeks) sildenafil; Tadalafil and sildenafil;   D02229
 D08514 		  [1] PDE5A   [3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   [16]
6,
46,
50,
51,
85,
86,
96,
113,
210,
211,
212,
225,
226,
278,
294,
299
 279   Simvastatin  [11] Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®;   D00434   [1] HMGCR   [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   [19]
6,
13,
15,
34,
46,
49,
51,
66,
79,
86,
89,
94,
158,
162,
195,
265,
298,
299,
310
 280   Sirolimus  [14] Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus;   D00753   [1] MTOR   [43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   [36]
2,
13,
15,
17,
34,
35,
36,
46,
49,
51,
60,
61,
62,
63,
65,
66,
67,
85,
86,
89,
96,
98,
137,
157,
158,
192,
222,
256,
277,
278,
279,
280,
281,
283,
285,
331
 281   Sirukumab  [3] Sirukumab; Sirukumab 100 mg; Sirukumab 50 mg;   D10080   [1] IL6   [46] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection   [2]
41,
46
 282   Sodium aurothiomalate  [2] Sodium aurothiomalate; Sodium aurothiomalate (intramuscular gold);   D00992   -   -   [1]
46
 283   Sodium chloride  [14] 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution;   D02056   -   -   [19]
6,
11,
13,
14,
17,
34,
46,
51,
53,
67,
78,
86,
97,
168,
193,
227,
228,
288,
299
 284   Sodium iodide  [2] Oncolytic measles virus encoding thyroidal sodium iodide symporter; Sodium iodide;   D04874
 D05328
 D05863 		  -   -   [3]
34,
46,
88
 285   Somatotropin  [2] Recombinant human somatotropin; Somatotropin;   D02691   [1] GHR   [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway   [18]
2,
3,
13,
19,
46,
74,
75,
78,
96,
113,
191,
193,
195,
236,
265,
274,
276,
299
 286   Sulfasalazine  [7] Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate plus sulfasalazine; Methotrexate-sulfasalazine-hydroxychloroquine; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Nsaids and sulfasalazine; Sulfasalazine; Sulfasalazine, ssz;   D00448   -   -   [3]
46,
94,
271
 287   Sulfate ion  -  -   -   -   [22]
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299
 288   Sunflower oil  [2] High oleic sunflower oil; Sunflower oil;   D09006   -   -   [3]
46,
240,
299
 289   TRU-015  [1] Tru-015;   -   -   -   [3]
46,
49,
222
 290   Tabalumab  [4] Ly2127399 (tabalumab); Tabalumab; Tabalumab auto-injector; Tabalumab prefilled syringe;   D10083   [1] TNFSF13B   [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis   [2]
46,
49
 291   Tacrolimus  [13] Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate;   D00107
 D08556 		  [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   [30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   [30]
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 292   Teriparatide  [4] Teriparatide; Teriparatide (forteo); Teriparatide [rdna origin] contains recombinant human parathyroid hormone (1-34); Teriparatide pen injector;   D06078   [1] PTH1R   [3] Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action   [7]
46,
65,
68,
70,
71,
235,
274
 293   Tetracycline  [4] Amoxicillin and tetracycline; Amoxicillin, metronidazole and tetracycline; Tetracycline; Tetracycline - statin - antimycotic;   D00201   -   -   [5]
13,
36,
46,
53,
97
 294   Ticagrelor  [1] Ticagrelor;   D09017   [1] P2RY12   [1] Platelet activation   [1]
46
 295   Tilmanocept  [3] Tc 99m tilmanocept; Tc99m-tilmanocept; Tilmanocept;   -   -   -   [1]
46
 296   Titanium  [1] Titanium;   -   -   -   [3]
46,
69,
70
 297   Tocilizumab  [25] Abatacept, rituximab or tocilizumab; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept;   D02596   [1] IL6R   [11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   [16]
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331
 298   Tofacitinib  [23] 15n2-tofacitinib; Chong kun dang tofacitinib tablet; Cp-690,550 (tofacitinib); In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Tofacitinib; Tofacitinib (xeljanz); Tofacitinib 10 mg; Tofacitinib 2 mg; Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5 mg twice daily; Tofacitinib 5mg [xeljanz] 1 year open-label extension; Tofacitinib 5mg oral tablet [xeljanz] 16 week trial; Tofacitinib 5mg po bid; Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate (proposed commercial formulation – debossed); Tofacitinib citrate cp-690550; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib;   D09970   [4] JAK1, JAK2, JAK3, TYK2   [34] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   [9]
46,
49,
50,
51,
84,
96,
97,
107,
271
 299   Topramezone  -  -   -   -   [7]
6,
13,
46,
50,
96,
97,
299
 300   Tramadol  [5] Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Tramadol; Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen;   D01355
 D08623 		  [1] OPRM1   [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   [5]
46,
70,
78,
226,
271
 301   Tranexamic acid  [2] Tranexamic acid; Tranexamic acid 100 mg/ml;   D01136   [1] PLG   [4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection   [5]
46,
70,
215,
227,
288
 302   Tranilast  [1] Tranilast;   D02027   -   -   [4]
46,
84,
106,
113
 303   Tregalizumab  [1] Tregalizumab;   -   -   -   [1]
46
 304   Triamcinolone  [10] Bladder instillation with triamcinolone acetonide; Bladder instillation without triamcinolone acetonide; Bupivacaine & triamcinolone acetonide; Intra plexus triamcinolone and bupivicaine injection; Triamcinolone; Triamcinolone acetonide; Triamcinolone acetonide and normal saline solution; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan);   D00385
 D00983
 D00984
 D00985
 D06216 		  [1] NR3C1   [1] Neuroactive ligand-receptor interaction   [18]
6,
10,
13,
35,
40,
41,
42,
43,
44,
45,
46,
56,
70,
90,
96,
97,
226,
298
 305   Tripterygium wilfordii whole  -  -   -   -   [8]
46,
66,
67,
96,
162,
222,
224,
271
 306   Tuberculin Purified Protein Derivative  -  -   -   -   [1]
46
 307   Ubidecarenone  -  D01065   -   -   [12]
2,
5,
6,
8,
10,
46,
57,
86,
113,
193,
214,
215
 308   Upadacitinib  [2] Upadacitinib; Upadacitinib (abt-494);   D10994   [1] JAK1   [26] EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   [6]
41,
46,
49,
96,
97,
271
 309   Ustekinumab  [32] Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Prednisone and ustekinumab treatment; Stelara (ustekinumab); Subcutaneous ustekinumab; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab (approximately 6 mg/kg); Ustekinumab 130 mg iv; Ustekinumab 180 mg; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 45 mg; Ustekinumab 6 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab 90 milligram (mg); Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv; Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab liquid in prefilled syringe; Ustekinumab sc; Ustekinumab sc injection;   D09214   [3] IL12A, IL12B, IL23A   [25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus   [16]
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271
 310   VX-702  [1] Vx-702;   -   -   -   [1]
46
 311   Valdecoxib  [1] Valdecoxib;   D02709   [1] PTGS2   [20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   [1]
46
 312   Vancomycin  [9] Inhaled vancomycin; Iv vancomycin hydrochloride; Oral vancomycin; Vancomycin; Vancomycin inhalation powder; Vancomycin pre-treat; Vancomycin pre-treatment; With u-vanco (vancomycin hydrochloride); Without u-vanco (vancomycin hydrochloride);   D00212
 D00926 		  -   -   [7]
46,
70,
94,
96,
97,
296,
299
 313   Veltuzumab  [2] Veltuzumab; Veltuzumab solution 75mg/ml;   D09031   [1] MS4A1   [1] Hematopoietic cell lineage   [1]
46
 314   Venlafaxine  [3] Efexor xl 75 mg (venlafaxine); Venlafaxine; Venlafaxine hydrochloride;   D00821
 D08670 		  [2] SLC6A2, SLC6A4   [2] Serotonergic synapse, Synaptic vesicle cycle   [3]
6,
13,
46
 315   Vitamin D  [16] 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); High-dose vitamin d (2000 iu per day); Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Standard-dose vitamin d (400iu per day); Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d in arm b; Vitamin d oil; Vitamin d powder;   -   -   -   [18]
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299
 316   Vitamin E  [8] Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium;   D02331   -   -   [12]
2,
6,
13,
20,
46,
49,
90,
96,
97,
206,
299,
317
 317   Warfarin  [4] S-warfarin; The generic name is warfarin and many producers will be involved; Warfarin; Warfarin 10 mg;   D00564
 D01280
 D08682 		  [2] NQO1, VKORC1   [5] Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis   [10]
6,
8,
13,
19,
46,
49,
66,
85,
88,
96
 318   Water  [13] 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep;   D00001   -   -   [22]
2,
5,
6,
13,
17,
19,
28,
35,
46,
53,
57,
63,
65,
67,
78,
84,
97,
193,
226,
271,
278,
299
 319   Yellow Fever Vaccine  [2] Yellow fever vaccine; Yellow fever vaccine (17d);   D06347   -   -   [7]
40,
44,
46,
50,
51,
52,
53
 320   Zoledronic acid  [4] Lonafarnib, zoledronic acid, and pravastatin; Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate;   D01968
 D06378
 D06379
 D08689 		  [1] FDPS   [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis   [11]
6,
13,
46,
65,
93,
95,
96,
271,
274,
299,
333
 321   keyhole limpet hemocyanin  [3] Keyhole limpet hemocyanin; Keyhole limpet hemocyanin (klh); Keyhole limpet hemocyanin (klh) neo-antigen;   -   -   -   [2]
13,
46

Back to top